Cancer Communications
indexed by SCI
BMC

doi: 10.1186/s40880-016-0092-4
Cell-free circulating tumor DNA in cancer
Zhen Qin, Vladimir A. Ljubimov, Cuiqi Zhou, Yunguang Tong and Jimin Liang
Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA; School of Life Science and Technology, Xidian University
[Abstract] Cancer is a common cause of death worldwide. Despite significant advances in cancer treatments, the morbidity and mortality are still enormous. Tumor heterogeneity, especially intratumoral heterogeneity, is a significant reason underlying difficulties in tumor treatment and failure of a number of current therapeutic modalities, even of molecularly targeted therapies. The development of a virtually noninvasive “liquid biopsy” from the blood has been attempted to characterize tumor heterogeneity. This review focuses on cell-free circulating tumor DNA (ctDNA) in the bloodstream as a versatile biomarker. ctDNA analysis is an evolving field with many new methods being developed and optimized to be able to successfully extract and analyze ctDNA, which has vast clinical applications. ctDNA has the potential to accurately genotype the tumor and identify personalized genetic and epigenetic alterations of the entire tumor. In addition, ctDNA has the potential to accurately monitor tumor burden and treatment response, while also being able to monitor minimal residual disease, reducing the need for harmful adjuvant chemotherapy and allowing more rapid detection of relapse. There are still many challenges that need to be overcome prior to this biomarker getting wide adoption in the clinical world, including optimization, standardization, and large multicenter trials.
Chinese Journal of Cancer 2016, Volume: 35, Issue 5
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)

[Google Scholar]


Cite this article

Zhen Qin, Vladimir A. Ljubimov, Cuiqi Zhou, Yunguang Tong and Jimin Liang. Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016, 35:36. doi:10.1186/s40880-016-0092-4


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China